School of Medicine Coronavirus Update:
Read for more details specific to medical students and School of Medicine events.

ACCORD

COBRE ACCORD FUNDING OPPORTUNITY

Deadline to submit CV and Letter of Interest, January 31, 2020 5 P.M.

Purpose

The COBRE ACCORD at Marshall University (P20GM121299-01A1) invites applications for one to two new Junior Investigators to join the program this Spring. This is a mentored funding opportunity worth research and salary support to help junior investigators successfully compete for larger extramural funding. The goal of the program is to develop an independent, NIH R01 funded investigator in obesity research at Marshall University.

Funding Details

The value of the award will be up to $400,000 over two years for the successful candidate. All the services of the cores of the COBRE ACCORD (i.e., Genomics, Imaging, Workforce, Biostatistics) will also be available.

Eligibility Requirements

  • Applicants should be in a full-time, tenure-track faculty position at the Assistant Professor level at Marshall University.
  • Applicants must have a Ph.D., M.D., or equivalent degree in Biological Sciences or Biomedical Sciences or a related field (e.g. Molecular Biology, Cell Biology).
  • 2-5 years of research experience at the Assistant Professor level.
  • Preference will be given to candidates with experience/interest in the field of obesity.
  • Candidates should also have a significant record of scientific accomplishments in in the form of publications, presentations and prior funding (e.g. career grant and/or pilot grants).

Applicant Requirements

  • Submit CV and Letter of Interest outlining their statement of research and career goals to Marlenea Brand
    • Based on the LOI and CV, selected candidates will be asked to submit a full application, including research proposal, budget, and relevant approvals (IACUC, IRB), by April 3, 2020.

Additional Information

Successful applicants will,

  • Have a joint appointment in the Department of Clinical and Translational Sciences at the Joan C. Edwards School of Medicine.
  • Receive dedicated mentoring by senior faculty.
  • Receive at least fifty percent protected time for research with salary support and an appropriate budget to conduct the project for up to two years.


Chairs of Search Committee 

Subha Arthur, PhD
Assitant Professor
brandm@marshall.edu

Travis Salisbury, PhD 
Associate Professor
brandm@marshall.edu

Maria Serrat, PhD
Associate Professor
brandm@marshall.edu

Sundaram
Uma Sundaram, MD
Chairman

Phone: (304) 691-1841
sundaramu@marshall.edu

Click Here to View BioSketch

My training and career to date has ideally positioned me to serve as the Principal Investigator and Program Director of the Center of Biomedical Research Excellence (COBRE) ACCORD. I have demonstrated a commitment to basic, clinical and translational research since my undergraduate training in Bioengineering at Johns Hopkins University during which my research at the National Institutes on Aging led to multiple co-authored publications in blood brain barrier drug entry and distribution modeling. Since graduating from the Medical College of Ohio, completing my residency in internal medicine at the University of Michigan and gastroenterology subspecialty training at Yale University, I have been actively involved in patient care, teaching and research funded by NIH, AGA, AHA, and CCFA. Over the years investigator initiated and multi center prospective clinical studies have been in Hepatitis C, inflammatory bowel disease, peptic ulcer disease and Barrett’s esophagus. The basic and translational research has been funded by NIH RO1s and currently an NIH RO1 (DK 67420) to study regulation of glucose and Na homeostasis as it pertain to diseases such as obesity and hypertension. Most recently, I was the Principal Investigator of the newly funded NIGMS IDeA Clinical Translational Research (CTR) U54 grant (1 U54 RR033567-01) at the West Virginia Clinical and Translational Science Institute (WVCTSI).

An Internal Advisory Committee (IAC) has been established with senior leaders from MU JCESOM having the necessary expertise and experience in the success of the ACCORD and the COBRE. In addition to support and oversight of the progress of the COBRE, the IAC will hold quarterly progress meetings, review pilot grant proposals, and provide programmatic recommendations to the COBRE PD/PI. The IAC is also integral to the Evaluation Plan proposed for this COBRE. Emphasizing the importance of this COBRE for the institution, the Dean, Dr. Shapiro will chair the IAC, which will consist of the following individuals:


Dr. Jaime Taylor 
Provost and Vice President of Academic Affairs 
Jaime.Taylor@marshall.edu

Jaime Taylor, who has a background in mathematics and computational physics, has held a faculty appointment at Austin Peay since 1996, when he joined the university with a B.S. in physics from Austin Peay (1990), and an M.S. (1991) and a Ph.D. (1995) in engineering science from the University of Tennessee Space Institute. Taylor has served as dean at Austin Peay since 2008, except for 2013-15, when he served as the institution’s interim provost and vice president for academic affairs. His research interests are in applications of biologically inspired algorithms or "soft computing" methods such as neural networks, fuzzy systems and genetic algorithms, and during the summers of 1996, 1997, 2001 and 2002, he served as a NASA Faculty Fellow at Marshall Space Flight Center in Huntsville, Ala. He also has conducted research at the U.S. Army Aviation and Missile Command at Redstone Arsenal in Huntsville, working on pulse-coupled neural networks for military and space-based applications.


Davies
John Maher, PhD
Vice President for Research
maherj@marshall.edu

Click Here to View BioSketch

The COBRE proposal requires scientific and managerial leadership at the institutional, state and inter-institutional level to develop the collaborative and participative atmosphere necessary for effective performance. I have a broad background in scientific leadership and management of cross-functional programs that will facilitate Marshall’s successful growth through the project and the successful achievement of multi-institutional project objectives. My expertise in strategic planning and management of large, complex projects will be applied at the steering team level to assure that the organizational foundation of the project components is properly designed and executed.


Sundaram
Monica Valentovic, PhD
Professor & Research Cluster Coordinator 

Phone: (304) 696-7332
valentov@marshall.edu

Click Here to View BioSketch

Obesity is a serious health condition within the United States that contributes to increasing the risk of other disease. The current statistics have reported that 33% of Americans are obese. In West Virginia the incidence of obesity is over 35%. Postmenopausal women who are obese have a higher risk of developing breast cancer. It is anticipated that almost 232,000 women will be diagnosed with breast cancer in 2015 and many of these individuals will be obese. The mechanism for the increased risk of cancer in obesity is not known and probably is mediated through a complex interaction of various factors. New treatment modalities are needed to address reducing the development of breast cancer.


Davies
Nader G. Abraham, PhD, Dr. H.C., FAHA
Professor of Medicine and Pharmacology
New York Medical College
nader_abraham@nymc.edu

Click Here to View BioSketch

My long-lasting research program centers on the biochemistry, biology and functional/clinical relevance of the heme-heme oxygenase (HO) system. As a postdoctoral fellow in the laboratory of Dr. Kappas at the Rockefeller University, I purified HO from rat and human liver and characterized its catalytic properties. I continued exploring the biology of HO throughout my scientific career in a prolific research program that made seminal contributions to this field of research.


Sundaram
Uma Sundaram, MD
Chairman

Phone: (304) 691-1841
sundaramu@marshall.edu

Click Here to View BioSketch

My training and career to date has ideally positioned me to serve as the Principal Investigator and Program Director of the Center of Biomedical Research Excellence (COBRE) ACCORD. I have demonstrated a commitment to basic, clinical and translational research since my undergraduate training in Bioengineering at Johns Hopkins University during which my research at the National Institutes on Aging led to multiple co-authored publications in blood brain barrier drug entry and distribution modeling. Since graduating from the Medical College of Ohio, completing my residency in internal medicine at the University of Michigan and gastroenterology subspecialty training at Yale University, I have been actively involved in patient care, teaching and research funded by NIH, AGA, AHA, and CCFA. Over the years investigator initiated and multi center prospective clinical studies have been in Hepatitis C, inflammatory bowel disease, peptic ulcer disease and Barrett’s esophagus. The basic and translational research has been funded by NIH RO1s and currently an NIH RO1 (DK 67420) to study regulation of glucose and Na homeostasis as it pertain to diseases such as obesity and hypertension. Most recently, I was the Principal Investigator of the newly funded NIGMS IDeA Clinical Translational Research (CTR) U54 grant (1 U54 RR033567-01) at the West Virginia Clinical and Translational Science Institute (WVCTSI).

Receipt of this COBRE grant will allow the individual junior investigators the unique opportunity for not only substantial financial support but also focused mentoring opportunities to aid them with the move to independence. Many IDeA institutions lack the senior funded faculty “bench strength.” While we have been actively growing this critical mass over the last few years at MU JCESOM, it behooves us to realize, mentoring requires a “village” having a deliberate infrastructure, not just individual mentors. Therefore, we had established a Mentoring Committee (MC) more than a year ago which includes not only individual project mentors, but also senior investigators from across the MU JCESOM with an equally impressive track record of investigation and mentorship. The junior investigators and mentors have been meeting regularly for more than a year to not only conduct review of research projects and grant proposals, but also to discuss career trajectories and pathways, promotion and tenure, time, fiscal and lab management, and networking. The MC is chaired by Dr. Elaine Hardman. In this capacity she will coordinate mentoring for this COBRE proposal. She has had an active and well-funded research laboratory for more than 20 years. As a Senior Faculty member in Biomedical Sciences, she has mentored newer faculty members including Drs. Piyali Dasgupta, Maria Serrat and Travis Salisbury. Drs. Dasgupta and Serrat have obtained NIH R15 funding and all are making good progress toward independence. Participation in ACCORD COBRE will greatly enhance this progress. Along with the MC, Dr. Hardman will coordinate mentoring activities to insure that mentors and junior investigators are meeting regularly and that junior investigators are receiving the expected guidance. She will review mentors’ quarterly reports prior to the IAC and EAC meetings and prepare a summary for these committees. She will review attendance at seminars, meetings with visiting professors and meeting presentations to ensure that junior investigators are meeting these obligations as outlined in their quarterly plans. The Mentoring Committee members are (in addition to individual project mentors in table below):

Sundaram
Richard Egleton, PhD
Associate Professor, Research Cluster Coordinator, & Co-Director of Biomedical Sciences Graduate Program 

Phone: (304) 696-3523
egleton@marshall.edu

Click Here to View BioSketch

I have two main roles in the CoBRE application. My primary role as co-director of the Biomedical Sciences program is to help mentor the COBRE mentees in graduate education. This includes guiding the CoBRE mentees through the various rules and regulations that govern graduate education, as well as being a resource for helping them develop mentoring plans and mentoring contracts with both undergraduate and graduate students that work in their laboratories. My secondary role in the grant is as another researcher with transport experience. My research over the last 20 years has focused on several aspects of transport and drug delivery during disease. This includes investigating the regulation of both transcellular transport and paracellular transport routes. Though these studies have largely been looking at the blood brain barrier, many of the core concepts (regulated ion transport, tight junctions) are common to other barrier tissues like the gut and kidney.


John L Fowlkes, MD
University of Kentucky
Director of Barnstable Brown Diabetes Center
Phone: 859-323-5321


Gress
Todd Gress, MD, MPH
MCRC Medical Director
gress@marshall.edu

Click Here to View BioSketch

I have the expertise, leadership, training, and motivation necessary to successfully support the Biostatistics and Study Design Resource proposed in this COBRE titled Appalachian Center for Cellular transport in Obesity Related Disorders (ACCORD). I have a strong background in Biostatistics and Epidemiology. I have been teaching Biostatistics and Epidemiology for over 15 years. During this time, I have assisted numerous students, residents, and faculty with their research projects. This effort has led to numerous abstracts, regional and national presentations, and publications. We have formalized this process of assisting trainees and faculty in research through development of the Biostatistics and Study Design Clinic in the Department of Clinical and Translational Sciences (DCTS). I also serve as the medical director for clinical trials, overseeing all clinical trials activity for the school of medicine, including investigator-initiated clinical trials. I am actively involved in all of the pilot award efforts in the school of medicine, having served in the roles of leader, reviewer, and pilot award selection committee member


Ruth Keri, PhD
Case Western Reserve University School of Medicine
Professor
Phone: 216-368-3495
keri@case.edu

For more than 17 years, my research has focused on the genomic and signaling mechanisms that control mammary gland development and cancer. As reflected by my position as a member of the steering committee for the Gene Expression and Genotyping Core Facility at CWRU, I have significant expertise in the acquisition and use of gene expression profiling data to identify novel factors that may control the phenotypes of breast cancer cells.  This has involved generating and using data from cell lines and genetically manipulated mouse models of breast cancer as well as evaluation of publicly available human breast cancer array data. I have designed and used mouse models of disease throughout my research career, including assessing the efficacy of therapeutic agents such as vitamin D analogs, rapamycin, and dasatinib in mammary cancer models. I also have significant experience assessing drug synergy, in vitro and in vivo. 


Philip Kern, MD
University of Kentucky
Director of the Center for Clinical and Translational Science
Phone: 859-323-2232


Davies
Jung Han Kim, PhD
Professor, Department of Pharmacology
kimj@marshall.edu

Click Here to View BioSketch

My experience and qualifications make me well suited for serving as a mentor in the project. Over the several years, I supervised more than one hundred undergraduate and twenty graduate students. I served as a Member in twenty graduate student thesis committees and served as Advisor/Chair for six M.S. and Ph.D. students. I have mentored three postdoctoral fellows who became a successful independent scientist. With my mentees I have produced multiple peer-reviewed publications. In addition, I have a solid background in genetics, nutritional sciences and physiology, with specific training and expertise in gene mapping, positional cloning, and physiological analysis. My research includes identifying genetic factors underlying obesity and type 2 diabetes and the related pathophysiological pathways. With my research endeavors I have developed useful animal models for obesity and type 2 diabetes including TALLYHO mice that are well served in the project. As PI on several Foundation- and NIH-funded grants, I have built a strong research program and have a track record of accomplished and productive research projects. 



Richard Kryscio, PhD
University of Kentucky Center of Clinical and Translational Science
Director, Biostatistics, Epidemiology & Research Design (BERD)
Phone: 859-257-4065
kyrscio@email.uky.edu


Davies
Hartmut H. Malluche, MD, F.A.C.P.
Chief, Division of Nephrology, Bone and Mineral Metabolism

Click Here to View BioSketch

I have trained over 90 students, residents, fellows and young faculty members for over 30 years. My particular focus is now on raising young faculty to become academically-oriented investigators rather than merely acquiring clinical knowledge that is applied to patients in a private practice setting. For decades, I have been conducting NIH-funded research in renal osteodystrophy. The following references highlight my experience and qualification for this project. 


Sundaram
Gary O. Rankin, PhD
Professor & Chair 

Phone: (304) 696-7319
rankin@marshall.edu

Click Here to View BioSketch

I am well qualified to serve as a mentor for junior scientists. I was Chair of the Department of Pharmacology from 1986-2005, and when my department was merged with the Department of Physiology, I was made Chair of the combined department, a position I still hold. Over the years, I have mentored numerous undergraduate (26), graduate (40) and medical students (18), postdoctoral fellows (7) and faculty members, both within and outside my department and institution. In addition, I am the principal investigator of the NIH-funded West Virginia IDeA Network of Biomedical Research Excellence (WV-INBRE). In this capacity, I oversee a state-wide network composed primarily of new investigators at primarily undergraduate institutions across West Virginia, and serve as mentor for several of them.


Sundaram
Uma Sundaram, MD
Chairman

Phone: (304) 691-1841
sundaramu@marshall.edu

Click Here to View BioSketch

My training and career to date has ideally positioned me to serve as the Principal Investigator and Program Director of the Center of Biomedical Research Excellence (COBRE) ACCORD. I have demonstrated a commitment to basic, clinical and translational research since my undergraduate training in Bioengineering at Johns Hopkins University during which my research at the National Institutes on Aging led to multiple co-authored publications in blood brain barrier drug entry and distribution modeling. Since graduating from the Medical College of Ohio, completing my residency in internal medicine at the University of Michigan and gastroenterology subspecialty training at Yale University, I have been actively involved in patient care, teaching and research funded by NIH, AGA, AHA, and CCFA. Over the years investigator initiated and multi center prospective clinical studies have been in Hepatitis C, inflammatory bowel disease, peptic ulcer disease and Barrett’s esophagus. The basic and translational research has been funded by NIH RO1s and currently an NIH RO1 (DK 67420) to study regulation of glucose and Na homeostasis as it pertain to diseases such as obesity and hypertension. Most recently, I was the Principal Investigator of the newly funded NIGMS IDeA Clinical Translational Research (CTR) U54 grant (1 U54 RR033567-01) at the West Virginia Clinical and Translational Science Institute (WVCTSI). 


Patrick Tso, PhD
University of Cincinnati College of Medicine
Professor, Mary M. Emery Chair of Pathology, Director of Cincinnati Mouse Metabolic Phenotyping Center
Phone: 513-558-2151
Patrick.tso@uc.edu

One of our research goals is to gain a better understanding of the mechanisms and factors regulating intestinal lipid absorption and the assembly and secretion of chylomicrons and very low density lipoproteins by the small intestine. The techniques we employ consist of conscious intestinal lymph fistula rats, lymph fistula mouse, intestinal epithelial cell culture, and also molecular biology. We are currently studying how bile salts are involved in the absorption of lipids. In addition, we are also studying the factors regulating the synthesis and secretion of apolipoproteins by the small intestine. The apolipoproteins we are studying are: apo AI, apo AIV, apo B, and apo CIII.


Sundaram
Monica Valentovic, PhD
Professor & Research Cluster Coordinator 

Phone: (304) 696-7332
valentov@marshall.edu

Click Here to View BioSketch

Obesity is a serious health condition within the United States that contributes to increasing the risk of other disease. The current statistics have reported that 33% of Americans are obese. In West Virginia the incidence of obesity is over 35%. Postmenopausal women who are obese have a higher risk of developing breast cancer. It is anticipated that almost 232,000 women will be diagnosed with breast cancer in 2015 and many of these individuals will be obese. The mechanism for the increased risk of cancer in obesity is not known and probably is mediated through a complex interaction of various factors. New treatment modalities are needed to address reducing the development of breast cancer.



Joseph I. Shapiro,
Dean of Joan C. Edwards
School of Medicine 
ShapiroJ@marshall.edu

Click Here for Biosketch 

Joseph Shapiro received a B.A. in Mathematics from the University of Pennsylvania in 1976 and his M.D. from UMDNJ-Rutgers Medical School in 1980. Dr. Shapiro trained in Internal Medicine at Georgetown University Hospital (1980-83) and Nephrology at the University of Colorado (1983-87). He rose through the academic ranks there and moved to the University of Toledo (formerly the Medical College of Ohio) as Professor of Medicine and chief of Nephrology in 1997. He became chairman of Medicine in 1999, serving until 2012 when became Vice President and Dean of the School of Medicine at Marshall University. 



Nalini Santanam, PhD
Professor & Research Cluster Coordinator 
santanam@marshall.edu

Biosketch to come, view Nalini Santanam's work here

Lisa Cassis, PhD
University of Kentucky College of Medicine
Vice President of Research
Professor of Pharmacology and Nutritional Sciences
Co-Director, Division of Nutritional Sciences
Graduate Faculty in Nutritional Sciences
Cardiovascular Research Center
MD/PhD Program Mentor
Phone: 859-323-4933
Email: lcassis@uky.edu


Pradeep Dudeja, PhD
University of Illinois at Chicago Department of Medicine
Professor of Physiology in Medicine Director, Scholarly Activities Division of Gastroenterology and Hepatology
Phone: 312-569-7434
Email: pkdudeja@uic.edu


Naji Abumrad, MD
Vanderbilt University Medical Center
Professor of Medicine
Phone: 615-343-2735
Email: naji.abumrad@vanderbilt.edu

Project 1 - Regulation of sodium dependent bile acid absorption in obesity

Mentor: Dr. Jung Han Kim

Click Here to View BioSketch

Arthur
Subha Arthur, PhD
Assistant Professor

arthursu@marshall.edu

Dysregulation of lipid homeostasis is a key characteristic of obesity, resulting in sequelae such as diabetes, cardiovascular diseases, fatty liver diseases, etc. Assimilation of lipids is entirely dependent on bile acid availability in the intestine. Bile acids are absorbed in the terminal ileal villus cell brush border membrane (BBM) via Na-bile acid-co-transporter (ASBT) requiring a favorable transcellular Na gradient provided by basolateral membrane (BLM) Na/K-ATPase. Novel preliminary findings suggest that in multiple species (including human), ASBT is upregulated secondary to Na/K-ATPase downregulation. Thus, the hypothesis of this project is that ASBT is uniquely regulated at the level of the cotransporter in the BBM, along with Na/K-ATPase in the BLM in intestinal cells during obesity. The observations of this study will result in novel data which will enhance our understanding of bile acid absorption, thereby, lipid assimilation dysregulation during obesity, and potentially lead to more efficacious treatment modalities.


Project 2 - Inhibition of Leucine-Stimulated Induction of mTOR1 to Suppress Breast Cancer in Obesity

Mentor: Dr. Uma Sundaram

Click Here to View BioSketch

Salisbury
Travis Salisbury, PhD
salisburyt@marshall.edu

Obesity is a risk factor for breast cancer, a disease that was diagnosed in nearly 3 million women in this country in 2015. Based on preliminary data, it is hypothesized that altered levels of adiponectin, leptin, and estrogen hormones found in obesity interact to activate the L-Type Amino Acid Transporter 1 (LAT1) gene. The LAT1 gene encodes an amino acid transporter that specifically promotes the uptake of neutral amino acids, including leucine. High intracellular levels of leucine are required for the activation of Mechanistic Target of Rapamycin (mTOR), a kinase that is critical to tumor growth. It is proposed that leucine-mediated increases in mTOR activity in breast cancer cells in obese women, compared with lean women lead to larger, more aggressive breast tumors that are more resistant to cancer therapy. It is anticipated that findings of this proposal will significantly enhance our understanding of obesity associated breast cancer and will potentially lead to new and more efficacious therapeutic options.


Project 3 - Dysregulated Growth Factor Transport and Accelerated Bone Elongation in Childhood Obesity

Mentor: Dr. Hartmut Malluche

Click Here to View BioSketch

Serrat
Maria Serrat, PhD

Serrat@marshall.edu

Appalachia (WV) leads the nation in childhood obesity with about 1 in 3 children already overweight or obese. Obese children have higher rates of linear growth, accelerated skeletal maturation, and diminished bone quality. These factors can contribute to painful and debilitating conditions such as limb bowing, joint instability, fractures, and slipped capital femoral epiphyses. Insulin-like growth factor (IGF)-I, is one of two essential hormones (Growth Hormone is the other) needed for proper bone growth and is altered in obesity. Novel preliminary data demonstrate that IGF binding proteins (IGFBPs) may regulate bone elongation by entrapping IGF-I and limiting its transport into the growth plate; however, IGFBPs levels are diminished in obesity. Thus, the overall hypothesis is that a decrease in local IGF binding proteins promotes bone lengthening by allowing more IGF-I transport into growth plates. Better understanding of how the perichondrium IGF binding proteins regulate IGF-I transport into growth plates will potentially result in IGFBP based therapies to modulate the rate of bone elongation in obesity, and thus minimize the associated obesity related morbidities of childhood.


Project 4 - To Be Determined (TBD)


Project 5 - Adipose derived secretome (ADS) uniquely regulates intestinal epithelial cell nutrient absorption during obesity

Mentor: Dr. Uma Sundaram

Click Here to View BioSketch


Soudamani Singh, PhD

singhs@marshall.edu

Obesity commonly results from an excess accumulation of adipose tissue when caloric consumption exceeds energy expenditure. During obesity, adipose-derived secretome (ADS) has been shown to influence many physiological processes, but the effects of ADS on intestinal epithelial nutrient transport processes are not known. Our preliminary studies showed that in obese Zucker rats (OZR) the nutrient transporters Na-glucose co-transporter 1 (SGLT1; SLC5A1) and Na-dependent glutamine co-transporter 1 (B0AT1; SLC6A19) are stimulated in intestinal epithelial villus cells compared to lean Zucker rats (LZR). These effects were also observed in vitro in rat intestinal epithelial IEC-18 cells showing stimulation of SGLT1 and B0AT1-mediated uptake of glucose and glutamine, respectively, by ADS from OZR, but not LZR. Thus, SGLT1 and B0AT1 are uniquely stimulated in villus cells during obesity and ADS appears to mediate this stimulation of glucose and glutamine assimilation via distinct mechanisms. These novel observations led to the hypothesis of this proposal – ADS mediates the unique alterations in SGLT1 and B0AT1 during obesity. The overall aim of this study is to elucidate the mechanisms underlying this unique regulation of SGLT1 and B0AT1 by ADS in obesity. The outcome of this study will undoubtedly enhance our understanding of the altered absorption of the primary nutrients into the enterocytes during obesity. Further, critical data obtained from this study could pave the way for novel, more efficacious and specific nutrition-based therapies for obesity.

Marlenea Brand, MPA
Administrative Director of Graduate Studies
Phone: 304-696-7399
brandm@marshall.edu

Rong Fan
Executive Administrative Assistant
Rong.fan@marshall.edu
Phone: (304) 691-1841

Catherine Sedergen 
Department Administrator 
sedergrenc@marshall.edu 
Phone: (304) 696-7339

Eric Robbins 
Business Manager
robbinse@marshall.edu
Phone: (304) 691-1844 or (304) 696-3558

Sundaram
Uma Sundaram, MD
Chairman

Phone: (304) 691-1841
sundaramu@marshall.edu

Click Here to View BioSketch

My training and career to date has ideally positioned me to serve as the Principal Investigator and Program Director of the Center of Biomedical Research Excellence (COBRE) ACCORD. I have demonstrated a commitment to basic, clinical and translational research since my undergraduate training in Bioengineering at Johns Hopkins University during which my research at the National Institutes on Aging led to multiple co-authored publications in blood brain barrier drug entry and distribution modeling. Since graduating from the Medical College of Ohio, completing my residency in internal medicine at the University of Michigan and gastroenterology subspecialty training at Yale University, I have been actively involved in patient care, teaching and research funded by NIH, AGA, AHA, and CCFA. Over the years investigator initiated and multi center prospective clinical studies have been in Hepatitis C, inflammatory bowel disease, peptic ulcer disease and Barrett’s esophagus. The basic and translational research has been funded by NIH RO1s and currently an NIH RO1 (DK 67420) to study regulation of glucose and Na homeostasis as it pertain to diseases such as obesity and hypertension. Most recently, I was the Principal Investigator of the newly funded NIGMS IDeA Clinical Translational Research (CTR) U54 grant (1 U54 RR033567-01) at the West Virginia Clinical and Translational Science Institute (WVCTSI).


Davies
John Maher, PhD
Vice President for Research
maherj@marshall.edu

Click Here to View BioSketch

The COBRE proposal requires scientific and managerial leadership at the institutional, state and inter-institutional level to develop the collaborative and participative atmosphere necessary for effective performance. I have a broad background in scientific leadership and management of cross-functional programs that will facilitate Marshall’s successful growth through the project and the successful achievement of multi-institutional project objectives. My expertise in strategic planning and management of large, complex projects will be applied at the steering team level to assure that the organizational foundation of the project components is properly designed and executed.


Davies
Donald A. Primerano, PhD
Professor; Microbiology
Section Head; and Co-Director,
Genomics and Bioinformatics Core Facility
primeran@marshall.edu

Click Here to View BioSketch

My primary research interests are in the discovery of chronic disease susceptibility genes using next generation sequencing, expression profiling and bioinformatic approaches. I currently serve as the Co-Director of the Genomics and Bioinformatics Core Facility (GABC) and as a member of the WV-IDeA Network of Biomedical Research Excellence (WV-INBRE) Administrative Core and WV Cancer Genomics Steering Committee. I have served as the Genomics Core Director from 1999-2011. As Co-Director, I have experience in (1) developing sequencing strategies and service relationships between the GABC and research networks needing genomic analyses, (2) providing overall direction to a core with evolving technologies and institutional responsibilities, (3) assisting individual investigators in designing genomic experiments and (4) providing training in genomic technologies.